Insulin Degludec plus Insulin Aspart (Novo Nordisk) in Phase III Diabetes trials

Insulin degludec plus insulin aspart from Novo Nordisk, reduced rates of hypoglycaemia by 58% in people with Type 2 Diabetes compared to biphasic insulin aspart when dosed twice-daily. The study was released by Novo Nordisk at the International Diabetes Federation (IDF) 21st World Diabetes Congress. In the study, insulin degludec/insulin aspart reduced the overall occurrence of hypoglycaemia during the day as well as at night (occurring between 23:00 and 05.59). Improvements in fasting plasma glucose (FPG) were also seen, with levels significantly lower in the insulin degludec/insulin aspart group vs biphasic insulin aspart (6.4 vs. 7.5 mmol/l). The study also found that insulin degludec plus insulin aspart was well tolerated and provided comparable overall glycaemic control to biphasic insulin aspart.A second study showed that rates of hypoglycaemia at night were reduced by 37% in people with Type 1 Diabetes using once-daily insulin degludec plus insulin aspart (with additional rapid-acting mealtime insulin doses for the remaining meals), compared to those using once-daily insulin detemir plus rapid-acting insulin at all main meals.The combination is filed at the FDA and in the EU.